Alaunos Therapeutics Inc (TCRT) - Total Liabilities
Based on the latest financial reports, Alaunos Therapeutics Inc (TCRT) has total liabilities worth $864.00K USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check TCRT financial resilience to evaluate the company's liquid asset resilience ratio.
Alaunos Therapeutics Inc - Total Liabilities Trend (2001–2025)
This chart illustrates how Alaunos Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Alaunos Therapeutics Inc total assets.
Alaunos Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Alaunos Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Optima Health plc
LSE:OPT
|
UK | GBX51.97 Million |
|
RevoluGROUP Canada Inc
V:REVO
|
Canada | CA$1.11 Million |
|
Public Policy Holding Company Inc
LSE:PPHC
|
UK | GBX129.81 Million |
|
Ophir Gold Corp
V:OPHR
|
Canada | CA$72.56K |
|
Railway Metrics & Dynamics Sweden AB
ST:RMDX
|
Sweden | Skr44.64 Million |
|
Southern Empire Resources Corp
V:SMP
|
Canada | CA$2.44 Million |
|
INEO Tech Corp
V:INEO
|
Canada | CA$5.16 Million |
Liability Composition Analysis (2001–2025)
This chart breaks down Alaunos Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See how leveraged is Alaunos Therapeutics Inc's balance sheet to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.77 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.33 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.57 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Alaunos Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Alaunos Therapeutics Inc (2001–2025)
The table below shows the annual total liabilities of Alaunos Therapeutics Inc from 2001 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $813.00K | +17.49% |
| 2024-12-31 | $692.00K | -64.62% |
| 2023-12-31 | $1.96 Million | -92.59% |
| 2022-12-31 | $26.38 Million | -28.33% |
| 2021-12-31 | $36.81 Million | +64.59% |
| 2020-12-31 | $22.36 Million | +58.56% |
| 2019-12-31 | $14.10 Million | +48.67% |
| 2018-12-31 | $9.49 Million | -95.31% |
| 2017-12-31 | $202.41 Million | +10.22% |
| 2016-12-31 | $183.65 Million | +176.77% |
| 2015-12-31 | $66.35 Million | +482.25% |
| 2014-12-31 | $11.40 Million | -49.06% |
| 2013-12-31 | $22.37 Million | -36.01% |
| 2012-12-31 | $34.96 Million | -4.22% |
| 2011-12-31 | $36.50 Million | +17.87% |
| 2010-12-31 | $30.97 Million | +43.15% |
| 2009-12-31 | $21.63 Million | +270.79% |
| 2008-12-31 | $5.83 Million | -8.22% |
| 2007-12-31 | $6.36 Million | +113.37% |
| 2006-12-31 | $2.98 Million | +30.07% |
| 2005-12-31 | $2.29 Million | +10782.70% |
| 2004-12-31 | $21.05K | -18.17% |
| 2003-12-31 | $25.72K | +44.21% |
| 2002-12-31 | $17.84K | +224.27% |
| 2001-12-31 | $5.50K | -- |
About Alaunos Therapeutics Inc
Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs. The company also develops hunTR TCR discovery platform to target driver mutations. Alaunos Th… Read more